Trial Profile
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2019
Price :
$35
*
At a glance
- Drugs Pentylenetetrazole (Primary)
- Indications Hypersomnia; Narcolepsy
- Focus Therapeutic Use
- Sponsors Balance Therapeutics
- 14 Jan 2019 Status changed from active, no longer recruiting to completed.
- 01 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.